#Switzerland #NLS Pharmaceutics #Zurich #Equity Financing #Kadimastem

NLS Pharmaceutics and Kadimastem Complete $1 Million Equity Financing

On June 30, 2025, NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss biopharmaceutical entity, revealed that it has successfully completed its second and final closing of a previously disclosed equity financing worth $3 million. This latest round, culminating in an additional $1 million, holds significant implications for their strategic partnership with Kadimastem Ltd., a company specializing in clinical-stage cell therapies. This financial infusion is not merely a number; it propels NLS towards an ambitious merger plan, boosting its capabilities in delivering therapies for central nervous system disorders.

In the latest closing, NLS Pharmaceutics issued 606,061 preferred shares at a conversion price of $1.65 each. This price reflects a 10% premium over the market share price on the date the initial agreement was signed back in March 2025. The transaction, undertaken on June 27, underscores the company’s commitment to advancing its agenda.

Ronen Twito, the Executive Chairman of Kadimastem, remarked on the financing as a crucial milestone for the company, emphasizing their continuous journey towards developing transformative therapies for patients battling severe health conditions. Twito expressed optimism about the journey ahead, highlighting investor confidence in the company’s mission.

This latest financing talks happen on the heels of a successful $2 million initial closing achieved in March 2025. Altogether, these efforts signal the robust investor confidence in NLS Pharmaceutics' strategic vision and their merger with Kadimastem—a partnership aimed at fostering advancements in both central nervous system and regenerative medicine.

NLS CEO, Alexander C. Zwyer, praised the successful equity financing as pivotal for enabling the company to further its plans with Kadimastem. He indicated that with strengthened financial reserves, they are well-equipped to navigate through the merger and push forward a diversified pipeline in the sphere of CNS and regenerative medicine, ensuring they are prepared to tackle the medical challenges ahead.

In terms of utilization, the funds generated from this financing round will be pivotal for supporting the pending merger with Kadimastem. This merger promises not only to enhance their cooperative capabilities but also ensure that both companies can continue their respective research and operational activities without financial constraints. Specifically, the funding will support the initial logistics associated with their Phase IIa clinical trial of AstroRx®, which is aimed at treating amyotrophic lateral sclerosis (ALS), and a Phase I study of IsletRx for diabetes treatment.

The plans for the merger are advancing diligently; however, they remain contingent on customary closing conditions and final regulatory and shareholder approvals. Both companies are optimistic about meeting these requirements promptly, allowing them to begin their next chapter of innovation in biopharmaceutical development.

In a world where patient needs evolve relentlessly, the collaboration between NLS Pharmaceutics and Kadimastem stands as an inspiring example of how strategic partnerships and sound financial planning can lead to innovative therapeutic solutions. This partnership combines Kadimastem’s pioneering cell therapy technologies with NLS's unique portfolio of biopharmaceuticals, creating a robust alliance aimed at making significant strides in biopharma.

As of now, both companies have laid down a solid foundation for advanced research and development activities, and investors are keenly watching as the landscape of CNS and metabolic disorder treatments continues to develop. Investors and analysts alike are urged to keep a close eye on these developments, as they may lead to significant breakthroughs in the treatment of some of the most pressing health issues of our time.

With every step taken by NLS and Kadimastem, the pathway to delivering impactful therapeutic solutions for patients seems increasingly clearer. Stakeholders across the board—from investors to healthcare professionals—are hopeful that these efforts materialize into transformational healthcare advancements that resonate deeply within the medical community.

This marks an exciting chapter for both companies, and as they merge their expertise and resources, the global healthcare landscape is set to benefit from their combined strengths.